Single-center study of intraoperative radiation therapy (IORT) using electronic brachytherapy

William Kenneth — Thu, 03 Feb 2022 00:00:00 +0000

objective Intraoperative radiation therapy (IORT) is safe and well tolerated in low-risk patients in two prospective randomized trials, TARGIT-A and ELIOT. Few long-term reported results for electronic IORT with Xoft Axxent systems. material/method A total of 100 patients (101 tumors) underwent partial mastectomy and intraoperative brachytherapy. Electronic brachytherapy via IORT was used to deliver 20 Gy in a single pass to the balloon surface before surgery was complete. The need for further intervention by surgery or radiation and the presence of clinical serousoma and tumor recurrence were noted. Patients were followed up regularly for at least 5 years.

result Patients ranged in age from 41 to 83, with a median of 66. Of the 101 tumors treated, T stage included 28.7% Tis, 2.0% T1mi, 11.9% T1a, 23.8% T1b, 30.7% T1c, and 3.0%. %T2. There were two recurrences at a median follow-up of 3.8 years. Eighteen patients required additional surgery or radiation therapy. Patients classified as 'acceptable' according to accelerated partial mammography eligibility criteria were less likely to require re-resection (suitable: 1.6%, cautious: 22.6%, unsuitable: 87.5%, P < 0.001) but required full breast examination . Symptomatic seromas were observed in 15% of patients. conclusion For appropriately selected women undergoing partial breast irradiation, IORT is a convenient and well-tolerated treatment option. Slurry formation rates were similar to those reported for multicomponent catheter-based systems.

Safety of nivolumab in combination with prior or concurrent radiotherapy in the treatment of hepatocellular carcinoma

Xin Chen Rubio , Mercedes Pedro Fernandez Lopez — Fri, 04 Feb 2022 00:00:00 +0000

We reviewed patients who underwent RT directed to the liver before or at the same time as nivolumab for HCC. Toxicity was assessed using the Common Term Criteria for Side Effects v5.0, up to disease progression, systemic therapy changes, additional liver-directed local area therapy (LRT), or death. We compared the prevalence (PR) of patients who underwent pre- and simultaneous RT. Children-Turcotte-Pugh (CTP) and albumin-bilirubin (ALBI) scores at 1, 3, and 6 months were compared to baseline.

Results We identified 55 patients with a median follow-up of 6.0 months. 34 (62%) received the previous RT and 21 (38%) received it at the same time. Grade 3 or higher toxicity occurred in 8 patients (17%). Grade 3+ toxicity was not different between the previous RT cohort for univariate analysis and the concurrent RT cohort (OR 1.91, 95% CI: 0.42, 8.59), but in the previous RT cohort for multivariate analysis. It was high (OR 5.42, 95% CI: 1.42, 20.67). ; p = 0.013). Average CTP scores increased from baseline (6.33) at months (7.04, 95% CI: 6.80 to 7.27) and 3 months (6.81, 95% CI: 6, 43 to 7.19) and then normalized. .. The average ALBI score increased from the monthly baseline (-1.93) (-1.75; 95% CI-1.84, -1.66), with no subsequent difference.

Journal of radiation oncology

Single-center study of intraoperative radiation therapy (IORT) using electronic brachytherapy

Safety of nivolumab in combination with prior or concurrent radiotherapy in the treatment of hepatocellular carcinoma